Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes

被引：0
|
作者：
William T. Cefalu
Kaj Stenlöf
Lawrence A. Leiter
John P. H. Wilding
Lawrence Blonde
David Polidori
John Xie
Daniel Sullivan
Keith Usiskin
William Canovatchel
Gary Meininger
机构：
[1] Louisiana State University,Pennington Biomedical Research Center
[2] Sahlgrenska University Hospital,Clinical Trial Center
[3] University of Toronto,Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St Michael’s Hospital, Division of Endocrinology and Metabolism
[4] University of Liverpool,Department of Obesity and Endocrinology
[5] Ochsner Medical Center,Department of Endocrinology, Diabetes, and Metabolic Diseases
[6] Janssen Research & Development,undefined
[7] LLC,undefined
[8] Janssen Research & Development,undefined
[9] LLC,undefined
来源：
Diabetologia | 2015年 / 58卷
关键词：
Body weight; Canagliflozin; Sodium glucose co-transporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1183 / 1187
页数：4
相关论文
共 50 条
  • [21] Reductions in HbA1c and Systolic Blood Pressure in Patients with Type 2 Diabetes Treated with Dapagliflozin
    Moran, Jason
    Katz, Arie
    Yeh, Helen
    DIABETES, 2015, 64 : A309 - A309
  • [22] Pramlintide, as an adjunct to premixed insulin, reduced HbA1c and body weight in patients with type 2 diabetes
    Darsow, T.
    Lorenzi, G.
    Zhang, B.
    Maier, H.
    Wilhelm, K.
    DIABETOLOGIA, 2008, 51 : S409 - S409
  • [23] Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes
    Ali, Ali Muhammed
    Martinez, Robert
    Al-Jobori, Hussein
    Adams, John
    Triplitt, Curtis
    DeFronzo, Ralph
    Cersosimo, Eugenio
    Abdul-Ghani, Muhammad
    DIABETES CARE, 2020, 43 (06) : 1234 - 1241
  • [24] POPULATION ATTRIBUTABLE RISK OF MICROVASCULAR EVENTS ASSOCIATED WITH HBA1C, BLOOD PRESSURE OR WEIGHT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Heintjes, E.
    Penning-van Beest, F. J. A.
    Parasuraman, S., V
    Grandy, S.
    Pollack, M.
    Herings, R.
    VALUE IN HEALTH, 2012, 15 (07) : A496 - A496
  • [25] Reductions in HbA1c and body weight with 2 years of exenatide treatment in overweight patients with type 2 diabetes
    Ivanyi, Tibor
    Guan, Xuesong
    Mac, Susanna
    Holcombe, John
    Blonde, Lawrence
    INTERNATIONAL JOURNAL OF OBESITY, 2007, 31 : S27 - S27
  • [26] Population Attributable Risk of Macrovascular Events Associated with HbA1c, Blood Pressure or Weight in Patients with Type 2 Diabetes Mellitus
    Heintjes, Edith M.
    Penning-van Beest, Fernie J. A.
    Parasuraman, Shreekant V.
    Grandy, Susan
    Pollack, Mike
    Herings, Ron M. C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 2 - 2
  • [27] Achieving the composite endpoint of A1C, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes
    Merton, Katherine
    Davies, Michael
    Vijapurkar, Ujjwala
    Inman, Doreen
    Meininger, Gary
    PHARMACOTHERAPY, 2016, 36 (12): : E231 - E231
  • [28] Population Attributable Risk of Microvascular Events Associated with HbA1c, Blood Pressure or Weight in Patients with Type 2 Diabetes Mellitus
    Heintjes, Edith M.
    Penning-van Beest, Fernie J. A.
    Parasuraman, Shreekant V.
    Grandy, Susan
    Pollack, Mike
    Herings, Ron M. C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 2 - 2
  • [29] Effects of garlic on blood glucose levels and HbA1c in patients with type 2 diabetes mellitus
    Phil, Rizwan Ashraf M.
    Khan, Rafeeq Alam
    Ashraf, Imran
    JOURNAL OF MEDICINAL PLANTS RESEARCH, 2011, 5 (13): : 2922 - 2928
  • [30] Achievement of individualized blood pressure and HbA1c targets in patients with hypertension and type-2 diabetes
    Schmieder, R. E.
    Tschoepe, D.
    Koch, C.
    Bramlage, P.
    Ouarrak, T.
    Gitt, A. K.
    EUROPEAN HEART JOURNAL, 2015, 36 : 539 - 539
12345